SCHEMBL5565734

SCHEMBL5565734

N#Cc1ccc2nc(C(=O)O)cc(N)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 1/20 0.48
CYP11B2 P19099 1/20 0.40
GRM2 Q14416 1/20 0.40
SLC22A12 Q96S37 2/20 0.38
DYRK1A Q13627 1/20 0.38
TERT O14746 1/20 0.38
HSD17B14 Q9BPX1 1/20 0.38
ALOX15 P16050 2/20 0.38
MEN1 O00255 1/20 0.38
MMP1 P03956 1/20 0.38
MMP9 P14780 1/20 0.38
BLM P54132 1/20 0.38
GNG2 P59768 1/20 0.38
GNB1 P62873 1/20 0.38
KMT2A Q03164 1/20 0.38
IGFBP5 P24593 1/20 0.37
APP P05067 1/20 0.37
MAP4K4 O95819 1/20 0.36
SCN9A Q15858 1/20 0.36
ADORA2A P29274 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5560772 0.85 CYP11B2 (0.42) PIN1CYP11B2GRM2DYRK1ATERT
SCHEMBL5561501 0.83 PIN1 (0.49) PIN1CYP11B2GRM2SLC22A12DYRK1A
SCHEMBL2909736 0.76 HSD17B14 (0.46) PIN1CYP11B2GRM2SLC22A12HSD17B14
SCHEMBL1314146 0.74 ALOX15 (0.58) GRM2ALOX15
SCHEMBL21660459 0.72 PIN1 (0.45) PIN1SLC22A12DYRK1AKMT2AAPP
SCHEMBL6080504 0.71 XDH (0.34) SLC22A12ALOX15KMT2AIGFBP5
SCHEMBL9330478 0.70 PIN1 (0.48) PIN1MEN1KMT2AADORA2A
SCHEMBL21044309 0.69 MCL1 (0.50) PIN1SLC22A12ALOX15MAP4K4SCN9A
SCHEMBL5884603 0.69 ADORA2A (0.50) MAP4K4ADORA2A
SCHEMBL3582506 0.69 NR4A2 (0.56) SLC22A12MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217794-B2 Compounds and methods for treatment of thrombosis DAIAMED, INC. (US) 2007-05-15 US disclosed
US-20050143317-A1 Compounds and methods for treatment of thrombosis EXITHERA PHARMACEUTICALS LLC 2005-06-30 US disclosed
WO-2004103270-A2 COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES LLC (US) 2004-12-02 WO disclosed
WO-2004089297-A2 COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES, LLC (US) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143317-A1 Compounds and methods for treatment of thrombosis SERPINC1, F11, F13B PIN1 3586/4885CYP11B2 2296/4885GRM2 4844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.